Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33328343.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4069.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.<i>See related article by Xu et al., p. 1003</i>.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms